$heff's $tation of $tocks & $olid DD

[$heff]

With PLX ($9.95) that seller could be a disgruntled shareholder as someone had reported that he has a history with TEVA & PLX. No one really knows, but what is important is that it does not affect the PDUFA date in front of the FDA or the company. We saw selling with AVNR in October by directors in the $3.00 range and investors were concerned as well. Many speculated it was because their pseudobulbar drug would not get approved. That was not the case and we got the approval of Nuedexta for Pseudobulbar Affect.
I am confident with the DD on this company. We have done our homework here and know what we own! The company (PLX) and the technology are solid and they have a large partner in Pfizer that is solid. If the recent selling concerns investors, then they should not buy shares of the company or any biotech for that matter as selling shares is becoming more the norm than not. That big investor selling shares may want to divert some of his holdings into another holding. I will note that just recently Baillie Gifford & Co (Scottish partnership)took at 7.18% stake in the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7354404


Best, $heff

Message in reply to:

PLX

Quote:
--------------------------------------------------------------------------------
...this guy (dr frost philip) was chairman of plx and teva also and resigned from board of plx in 2007. sold 1.7 million shares recentely in 2011...
--------------------------------------------------------------------------------

Thank you for those articles. WOW. Given that the man was a former member of the BOD (3 years ago), it concerns me greatly that he would sell so many shares shortly before an FDA decision.

So he got $16.3 million, but there's that nagging question...

Despite the presence of the SPA, does Dr. Frost's decision to sell so many shares give you (or anyone else) pause?

Thank you.